Artemis Therapeutics
Artemis Therapeutics is profiled as a private biopharmaceutical company headquartered in New York, United States, though available source data describes an Indonesian online gaming top-up and account-resale marketplace.
- Company typePrivate
- Founded-
- HeadquartersNew York, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Artemis Therapeutics does
Per the firmographic profile, Artemis Therapeutics is described as a private, for-profit biopharmaceutical company headquartered in New York, United States, with a corporate website at artemis-therapeutics.com. However, the substantive source material contains no reference to biopharmaceutical activity, drug development, or related scientific operations. Instead, the source data describes an Indonesian online gaming top-up and account-resale marketplace branded as Koin138 / PPixelMart, which offers instant automated top-ups for titles such as Mahjong Ways, Gates of Olympus, Sweet Bonanza, Starlight Princess, Wild Bounty Showdown, and Wild Bandito, alongside vouchers and account resale protected by an escrow (rekber) system. The platform supports Indonesian payment methods including DANA, OVO, GoPay, ShopeePay, bank transfer, QRIS, and mobile credit (pulsa), and operates a 24-hour live-chat customer support function with cashback and promotional incentives for registered users.
Artemis Therapeutics firmographics
Firmographics- Name
- Artemis Therapeutics
- Website
- https://artemis-therapeutics.com
- Company type
- Private
- Headcount range
- 1–10 employees
- Short description
- Artemis Therapeutics is profiled as a private biopharmaceutical company headquartered in New York, United States, though available source data describes an Indonesian online gaming top-up and account-resale marketplace.
- Ownership category
- akta.pro rank
Where Artemis Therapeutics is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Markets served
Artemis Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D
Distribution channels2 records
Marketing channels2 records
Artemis Therapeutics product offering
Product offeringCore offering
Artemis Therapeutics is a biopharmaceutical company operating in the therapeutics sector. The firm's core activity centers on biopharmaceutical development, as indicated by its company classification. No specific therapeutic products, pipeline assets, or service offerings are documented in the available source material.
Differentiator
Problem solved
Functional benefit
Companies that use Artemis Therapeutics
Customer profileSegments1 record
Artemis Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Artemis Therapeutics partnerships and signals
Strategic signalRecent moves4 records
Expansion highlights3 records
Artemis Therapeutics competitors and assessment
Company assessmentBroad incumbents
- Ionis Pharmaceuticals: Established biopharmaceutical company with a broad RNA-targeted therapeutics pipeline; relevant incumbent comparable given Artemis is in the biopharma space without a confirmed modality.
Emerging players
- Black Diamond Therapeutics: Clinical-stage precision oncology biotech with operations historically linked to the New York area; comparable as another private/small-cap biopharmaceutical venture where Artemis's specific therapeutic focus is undisclosed.
- Arcturus Therapeutics: Clinical-stage biopharmaceutical company developing nucleic-acid-based medicines with a presence in the broader NYC biotech ecosystem; relevant generic biopharma peer given Artemis's modality is not disclosed.
- Madrigal Pharmaceuticals: Small-cap biopharmaceutical company that progressed a single-asset NASH program from early stage to FDA approval; serves as a useful comparable for the trajectory an under-disclosed biopharma could follow.
- Crinetics Pharmaceuticals: Clinical-stage biopharmaceutical company developing peptide therapeutics for endocrine diseases; comparable as a small-mid cap biopharma with a focused pipeline.
Market position
Strengths2 records
Weaknesses3 records
Competitive moat3 records
Key risks5 records
Key highlights2 records
Customer concentration
Artemis Therapeutics social profiles
Digital presenceArtemis Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Artemis Therapeutics leadership team
Management profileNumber of profiles
Artemis Therapeutics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Artemis Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Artemis Therapeutics
What does Artemis Therapeutics do?
Artemis Therapeutics is a biopharmaceutical company operating in the therapeutics sector. The firm's core activity centers on biopharmaceutical development, as indicated by its company classification. No specific therapeutic products, pipeline assets, or service offerings are documented in the available source material.
When was Artemis Therapeutics founded?
Artemis Therapeutics was founded in -1. It employs 1 to 10 people.
Where is Artemis Therapeutics based?
Artemis Therapeutics is headquartered in New York, United States, in the North America region.
Who are Artemis Therapeutics's main competitors?
Ionis Pharmaceuticals is listed as a broad incumbent. Emerging players are Black Diamond Therapeutics, Arcturus Therapeutics, Madrigal Pharmaceuticals and Crinetics Pharmaceuticals.
Does Artemis Therapeutics have an API?
No public API is recorded for Artemis Therapeutics.